Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study-Reference-Cited by-同舟云学术

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study

Published:2019-10 Issue:10 Volume:20 Page:1454-1466
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Schuler Martin,Cho Byoung Chul,Sayehli Cyrus Michael,Navarro Alejandro,Soo Ross A,Richly Heike,Cassier Philippe Alexandre,Tai David,Penel Nicolas,Nogova Lucia,Park Se Hoon,Schostak Martin,Gajate Pablo,Cathomas Richard,Rajagopalan Prabhu,Grevel Joachim,Bender Sebastian,Boix Oliver,Nogai Hendrik,Ocker Matthias,Ellinghaus Peter,Joerger Markus

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application;Chae;Oncotarget,2017

2. FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (review);Katoh;Int J Mol Med,2016

3. A phase Ib open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers;Paik;Clin Cancer Res,2017

4. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

5. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors;Tabernero;J Clin Oncol,2015

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial;BMC Cancer;2024-08-13

2. Applications of Nanopore sequencing in precision cancer medicine;International Journal of Cancer;2024-07-19

3. Landscape of targeted therapies for advanced urothelial carcinoma;Exploration of Targeted Anti-tumor Therapy;2024-06-21

4. Targeting FGFR for cancer therapy;Journal of Hematology & Oncology;2024-06-03

5. Exploring the potential of thiophene derivatives as dual inhibitors of β-tubulin and Wnt/β-catenin pathways for gastrointestinal cancers in vitro;Heliyon;2024-06